These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 31911031)

  • 21. Evaluation of early immune response-survival relationship in cynomolgus macaques after Anthrax Vaccine Adsorbed vaccination and Bacillus anthracis spore challenge.
    Sivko GS; Stark GV; Tordoff KP; Taylor KL; Glaze E; VanRaden M; Schiffer JM; Hewitt JA; Quinn CP; Nuzum EO
    Vaccine; 2016 Dec; 34(51):6518-6528. PubMed ID: 27155494
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunogenicity and safety of a novel recombinant protective antigen anthrax vaccine (GC1109), a randomized, single-blind, placebo controlled phase II clinical study.
    Kang CK; Kim NH; Kim CJ; Rhie GE; Jo SK; Ahn M; Kang J; Choe PG; Park WB; Kim NJ; Oh MD
    Vaccine; 2019 Jun; 37(29):3820-3824. PubMed ID: 31151800
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A novel live attenuated anthrax spore vaccine based on an acapsular Bacillus anthracis Sterne strain with mutations in the htrA, lef and cya genes.
    Chitlaru T; Israeli M; Rotem S; Elia U; Bar-Haim E; Ehrlich S; Cohen O; Shafferman A
    Vaccine; 2017 Oct; 35(44):6030-6040. PubMed ID: 28342664
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Protective effect of Bacillus anthracis surface protein EA1 against anthrax in mice.
    Uchida M; Harada T; Enkhtuya J; Kusumoto A; Kobayashi Y; Chiba S; Shyaka A; Kawamoto K
    Biochem Biophys Res Commun; 2012 May; 421(2):323-8. PubMed ID: 22507985
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Bivalent Protein r-PAbxpB Comprising PA Domain IV and Exosporium Protein BxpB Confers Protection Against
    Majumder S; Das S; Somani VK; Makam SS; Kingston JJ; Bhatnagar R
    Front Immunol; 2019; 10():498. PubMed ID: 30941133
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bacillus subtilis spore vaccines displaying protective antigen induce functional antibodies and protective potency.
    Oh Y; Kim JA; Kim CH; Choi SK; Pan JG
    BMC Vet Res; 2020 Jul; 16(1):259. PubMed ID: 32723323
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Protection of farm goats by combinations of recombinant peptides and formalin inactivated spores from a lethal Bacillus anthracis challenge under field conditions.
    Koehler SM; Buyuk F; Celebi O; Demiraslan H; Doganay M; Sahin M; Moehring J; Ndumnego OC; Otlu S; van Heerden H; Beyer W
    BMC Vet Res; 2017 Jul; 13(1):220. PubMed ID: 28701192
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunological correlates for protection against intranasal challenge of Bacillus anthracis spores conferred by a protective antigen-based vaccine in rabbits.
    Weiss S; Kobiler D; Levy H; Marcus H; Pass A; Rothschild N; Altboum Z
    Infect Immun; 2006 Jan; 74(1):394-8. PubMed ID: 16368995
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A synthetic peptide vaccine directed against the 2ß2-2ß3 loop of domain 2 of protective antigen protects rabbits from inhalation anthrax.
    Oscherwitz J; Yu F; Cease KB
    J Immunol; 2010 Sep; 185(6):3661-8. PubMed ID: 20696862
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An in vivo passive protection assay for the evaluation of immunity in AVA-vaccinated individuals.
    Hewetson JF; Little SF; Ivins BE; Johnson WM; Pittman PR; Brown JE; Norris SL; Nielsen CJ
    Vaccine; 2008 Aug; 26(33):4262-6. PubMed ID: 18586363
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anthrax Vaccine Precipitated Induces Edema Toxin-Neutralizing, Edema Factor-Specific Antibodies in Human Recipients.
    Dumas EK; Gross T; Larabee J; Pate L; Cuthbertson H; Charlton S; Hallis B; Engler RJM; Collins LC; Spooner CE; Chen H; Ballard J; James JA; Farris AD
    Clin Vaccine Immunol; 2017 Nov; 24(11):. PubMed ID: 28877928
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Significant passive protective effect against anthrax by antibody to Bacillus anthracis inactivated spores that lack two virulence plasmids.
    Enkhtuya J; Kawamoto K; Kobayashi Y; Uchida I; Rana N; Makino SI
    Microbiology (Reading); 2006 Oct; 152(Pt 10):3103-3110. PubMed ID: 17005989
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Defining a serological correlate of protection in rabbits for a recombinant anthrax vaccine.
    Little SF; Ivins BE; Fellows PF; Pitt ML; Norris SL; Andrews GP
    Vaccine; 2004 Jan; 22(3-4):422-30. PubMed ID: 14670324
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sequential B-cell epitopes of Bacillus anthracis lethal factor bind lethal toxin-neutralizing antibodies.
    Nguyen ML; Crowe SR; Kurella S; Teryzan S; Cao B; Ballard JD; James JA; Farris AD
    Infect Immun; 2009 Jan; 77(1):162-9. PubMed ID: 18981257
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Human monoclonal antibodies against anthrax lethal factor and protective antigen act independently to protect against Bacillus anthracis infection and enhance endogenous immunity to anthrax.
    Albrecht MT; Li H; Williamson ED; LeButt CS; Flick-Smith HC; Quinn CP; Westra H; Galloway D; Mateczun A; Goldman S; Groen H; Baillie LW
    Infect Immun; 2007 Nov; 75(11):5425-33. PubMed ID: 17646360
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Protection against anthrax lethal toxin challenge by genetic immunization with a plasmid encoding the lethal factor protein.
    Price BM; Liner AL; Park S; Leppla SH; Mateczun A; Galloway DR
    Infect Immun; 2001 Jul; 69(7):4509-15. PubMed ID: 11401993
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A plant based protective antigen [PA(dIV)] vaccine expressed in chloroplasts demonstrates protective immunity in mice against anthrax.
    Gorantala J; Grover S; Goel D; Rahi A; Jayadev Magani SK; Chandra S; Bhatnagar R
    Vaccine; 2011 Jun; 29(27):4521-33. PubMed ID: 21504775
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunogenicity of anthrax recombinant peptides and killed spores in goats and protective efficacy of immune sera in A/J mouse model.
    Ndumnego OC; Koehler SM; Crafford JE; Beyer W; van Heerden H
    Sci Rep; 2018 Nov; 8(1):16937. PubMed ID: 30446695
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunogenicity and efficacy of an anthrax/plague DNA fusion vaccine in a mouse model.
    Albrecht MT; Eyles JE; Baillie LW; Keane-Myers AM
    FEMS Immunol Med Microbiol; 2012 Aug; 65(3):505-9. PubMed ID: 22515653
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of a novel chimeric PA-LF antigen of Bacillus anthracis, its immunological characterization and evaluation as a future vaccine candidate in mouse model.
    Varshney A; Kumar M; Nagar DP; Pal V; Goel AK
    Biologicals; 2019 Sep; 61():38-43. PubMed ID: 31416791
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.